A preliminary report comparing the effect of Asafoetida with oral contraceptive on polycystic ovarian syndrome in a double-blind randomized trial.

Najmeh Dehparvar, Ahia Garshasbi, A. Niasari-Naslaji, Fatemeh Alijaniha, Mohammad Gholami Fesharaki, Farzaneh Ghaffari, Mohsen Naseri
In: Avicenna journal of phytomedicine · 2024 · vol. 14(3) , pp. 278–288 · doi:10.22038/ajp.2023.23122 · PMID:39086865 · W4401237398
article OA: green CC0
📄 Open PDF View on OpenAlex View on PubMed View at publisher

Abstract

Objective: L. (Asafoetida) was recommended for treating PCOS. The present study was conducted to compare the effect of Asafoetida with oral contraceptive tablets on PCOS patients. Materials and Methods: Patients with PCOS (n=30) were enrolled in a double-blind randomized clinical trial. On Day 5 of the menstrual cycle, patients received two periods of 21-day treatment, with 7 days rest between the two treatments. On a daily basis, half of the patients (n=15) received Asafoetida (1 g), and the rest received low dose oral contraceptive (LD; one tablet). Menstrual status, anthropometric characteristics, hematology and biochemistry parameters, ovarian ultrasound examination and hirsutism were evaluated prior to the initiation of the experiment and 14 days after the end of treatment. The occurrence of menstrual cycles and pregnancy was assessed eight months after the end of treatment. Results: The incidence of pregnancy was greater in patients who received Asafoetida compared to those who received LD (p=0.019). The time intervals between menstrual cycles became shorter in both groups (p<0.05). The occurrence of regular menstrual cycles remained longer in the Asafoetida compared to the LD group (p=0.001). Concentrations of triglycerides, cholesterol, HDL and LDL were significantly increased after treating with LD (p<0.05). Conclusion: In PCOS patients, the occurrence of regular menstrual cycles and the incidence of pregnancy were improved following treatment with Asafoetida. This medicament could be considered a safe treatment for patients with PCOS.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

References (32)

SciLite annotations

organisms 35
ferula assa-foetida ferula assa-foetida ferula assa-foetida ferula assa-foetida pseudosperma mediterraneum ferula assa-foetida pseudosperma mediterraneum ferula assa-foetida mosquito plant umbelliferae ferula assa-foetida ferula assa-foetida noordeloos 2009062 ferula assa-foetida ferula foetida ferula assa-foetida ferula assa-foetida ferula assa-foetida ferula assa-foetida ferula assa-foetida ferula assa-foetida ferula assa-foetida ferula assa-foetida ferula assa-foetida ferula assa-foetida ferula assa-foetida rattus sp. humans rattus sp. ferula assa-foetida ferula assa-foetida ferula assa-foetida ferula assa-foetida ferula assa-foetida noordeloos 2009062
chemicals 30
triglyceride cholesterol estrogen progestin triglyceride mineral testosterone gallic acid estradiol norgestrel testosterone deoxy sugar triglyceride cholesterol lipoprotein lipoprotein triglyceride cholesterol testosterone estrogen progesterone silver lipid triglyceride cholesterol cholesterol triglyceride testosterone gellan gum silver

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
scilite
last seen: 2026-05-18T04:26:01.642840+00:00
License: CC0 · commercial use OK